This study is in progress, not accepting new patients
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
Summary
- Eligibility
- for people ages 25-65 (full criteria)
- Location
- at UC Davis UCSD
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT03761849
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated